Vera Therapeutics, Inc. $VERA Stock Position Lifted by Trexquant Investment LP

Trexquant Investment LP boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 187.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,777 shares of the company’s stock after purchasing an additional 40,913 shares during the period. Trexquant Investment LP owned about 0.10% of Vera Therapeutics worth $1,508,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Vera Therapeutics by 8.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock worth $114,212,000 after buying an additional 377,783 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Vera Therapeutics by 18.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company’s stock valued at $40,243,000 after buying an additional 260,188 shares in the last quarter. Paradigm Biocapital Advisors LP raised its stake in shares of Vera Therapeutics by 31.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company’s stock valued at $60,785,000 after buying an additional 340,488 shares in the last quarter. Woodline Partners LP boosted its position in Vera Therapeutics by 20.1% in the fourth quarter. Woodline Partners LP now owns 1,202,466 shares of the company’s stock valued at $50,852,000 after buying an additional 201,573 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its position in Vera Therapeutics by 130.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company’s stock valued at $48,634,000 after buying an additional 650,000 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VERA has been the topic of a number of research analyst reports. Wolfe Research reissued a “peer perform” rating on shares of Vera Therapeutics in a report on Monday, August 4th. Guggenheim reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. HC Wainwright reiterated a “buy” rating and issued a $85.00 price target (up from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. Scotiabank restated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $63.00.

Insider Activity

In other news, Director Patrick G. Enright acquired 209,393 shares of the stock in a transaction dated Monday, June 23rd. The stock was bought at an average price of $20.87 per share, with a total value of $4,370,031.91. Following the completion of the purchase, the director directly owned 3,569,522 shares of the company’s stock, valued at $74,495,924.14. This represents a 6.23% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.30% of the stock is owned by corporate insiders.

Vera Therapeutics Trading Up 10.5%

Shares of Vera Therapeutics stock opened at $24.19 on Friday. The firm has a 50-day moving average of $22.19 and a 200-day moving average of $23.39. The stock has a market cap of $1.54 billion, a PE ratio of -6.76 and a beta of 1.17. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 17.03 and a current ratio of 17.03.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same period last year, the company earned ($0.62) EPS. As a group, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.